Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (1979)	11/7/2000 7:58:49 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Michael, <<natrecor>> real market potential for the drug? This is a very tough one to judge. There's been nothing new out there for severe congestive heart failure for years (decades?). What is out there is by all accounts tricky to use and doesn't always work well. So will something new catch on, or will doctors cautiously stick with what they know? Quite a lot might depend on the label they get, but I guess I'm fairly cautious on how quickly they can grow their sales. That said, with approval and a decent marketing agreement the stock should do fairly well. They're not a one-drug company, and with approval in hand they could easily get munched. Peter